According to a media report, the US pharmaceutical company Merck is no longer in talks to buy the cancer drug developer Revolution Medicines. The talks cooled after the companies were unable to reach an agreement on the price, the Wall Street Journal reported on Sunday, citing insiders. However, it is possible that talks could be resumed or another buyer could emerge for Revolution.
